蛋白酶体通路抑制作为NF2相关脑膜瘤和神经鞘瘤的潜在治疗
本研究基于前期高通量药物筛选,在NF2临床前模型中评估乌布替尼(ixazomib)、pevonedistat与TAK-243三种泛素-蛋白酶体通路(UPP)抑制剂。结果显示ixazomib与TAK-243可降低细胞活力并诱导凋亡,下调c-KIT、PDGFRα及E3泛素连接酶SKP2,上调内质网应激介导的未折叠蛋白反应(UPR)相关基因;小鼠模型中肿瘤生长延迟。
要点
- ixazomib与TAK-243在脑膜瘤和神经鞘瘤模型中降低细胞活力并诱导凋亡,pevonedistat未显示此作用。
- ixazomib或TAK-243下调c-KIT、PDGFRα及E3泛素连接酶SKP2,上调UPR相关基因。
- 小鼠原位NF2缺陷脑膜瘤与神经鞘瘤模型中观察到肿瘤生长延迟,提示治疗潜力。
核心结论
- 蛋白酶体通路抑制剂在脑膜瘤和神经鞘瘤临床前模型中显示疗效,为NF2患者一种有前景的新型治疗策略奠定基础。
研究设计与样本
- 研究利用人原代与永生化脑膜瘤(MN)细胞系、CRISPR修饰的施万细胞(SCs)及小鼠Nf2-/-施万细胞,进行剂量反应测试、基于流式细胞术的Annexin V与细胞周期分析及RNA测序;并在原位NF2缺陷脑膜瘤与神经鞘瘤小鼠模型中评估体内疗效。
主要发现
- 三种UPP抑制剂测试中,ixazomib或TAK-243强烈降低细胞活力并诱导凋亡,pevonedistat未显示此作用。
- 体外分析显示ixazomib或TAK-243下调c-KIT与PDGFRα表达及E3泛素连接酶SKP2,同时上调与内质网应激介导的未折叠蛋白反应(UPR)激活相关的基因。
- 小鼠模型体内治疗显示肿瘤生长延迟,提示治疗潜力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neurofibromatosis 2 (NF2) is an inherited disorder caused by bi-allelic inactivation of the NF2 tumor suppressor gene. NF2-associated tumors, including schwannoma and meningioma, are resistant to chemotherapy, often recurring despite surgery and/or radiation, and have generally shown cytostatic response to signal transduction pathway inhibitors, highlighting the need for improved cytotoxic therapies. METHODS: Leveraging data from our previous high-throughput drug screening in NF2 preclinical models, we identified a class of compounds targeting the ubiquitin-proteasome pathway (UPP), and undertook studies using candidate UPP inhibitors, ixazomib/MLN9708, pevonedistat/MLN4924, and TAK-243/MLN7243. Employing human primary and immortalized meningioma (MN) cell lines, CRISPR-modified Schwann cells (SCs), and mouse Nf2-/- SCs, we performed dose response testing, flow cytometry-based Annexin V and cell cycle analyses, and RNA-sequencing to identify potential underlying mechanisms of apoptosis. In vivo efficacy was also assessed in orthotopic NF2-deficient meningioma and schwannoma tumor models. RESULTS: Testing of three UPP inhibitors demonstrated potent reduction in cell viability and induction of apoptosis for ixazomib or TAK-243, but not pevonedistat. In vitro analyses revealed that ixazomib or TAK-243 downregulates expression of c-KIT and PDGFRα, as well as the E3 ubiquitin ligase SKP2 while upregulating genes associated with endoplasmic reticulum stress-mediated activation of the unfolded protein response (UPR). In vivo treatment of mouse models revealed delayed tumor growth, suggesting a therapeutic potential. CONCLUSIONS: This study demonstrates the efficacy of proteasomal pathway inhibitors in meningioma and schwannoma preclinical models and lays the groundwork for use of these drugs as a promising novel treatment strategy for NF2 patients.
引用
- Bhattacharyya S, Oblinger JL, Beauchamp RL, et al. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma. Neuro Oncol. 2023. PMID: 36806881. doi:10.1093/neuonc/noad037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。